Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04088188 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
A Phase 1 study, sponsored by Academic and Community Cancer Research United.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04088188 is a Phase 1 study that was terminated before completion, run by Academic and Community Cancer Research United. The registered enrollment target is 8 participants.
The verdict
NCT04088188, a Phase 1 study, was terminated before completion, sponsored by Academic and Community Cancer Research United.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of gemcitabine and cisplatin when given together with ivosidenib or pemigatinib in treating patients with cholangiocarcinoma that cannot be removed with surgery (unresectable) or has spread to other places in the body (metastatic). Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ivosidenib and pemigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine and cisplatin with ivosidenib or pemigatinib may work better in treating patients with cholangiocarcinoma compared to gemcitabine and cisplatin alone.
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Ivosidenib
- DRUG Pemigatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-01-25 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04088188
The ClinicalTrials.gov registry entry for NCT04088188 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT04088188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04088188 about?
NCT04088188 is a clinical study titled "Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma". This phase I trial studies the side effects and best dose of gemcitabine and cisplatin when given together with ivosidenib or pemigatinib in treating patients with cholangiocarcinoma that cannot be removed with surgery (unresectable) or has spread to other places in the body (metastatic). Chemothera...
What is the current status of trial NCT04088188?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-01-25. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT04088188?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Ivosidenib (DRUG), Pemigatinib (DRUG).
Who is sponsoring clinical trial NCT04088188?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.